Related Experiment Video
Updated: May 25, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Long QT syndrome and torsade de pointes after anthracycline chemotherapy
N Colombo1, M Civelli, D Cardinale
1Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
Abstract:
Anthracycline chemotherapy, which represents the treatment of choice for many hematologic and metastatic cancers, unfortunately carries with it the possibility of both early cardiotoxic phenomena, occuring during chemotherapy, and also late cardiotoxic manifestations, occuring even months or years from the completion of treatment.THE CLINICAL MANIFESTATIONS OF EARLY CARDIOTOXICITY COMMONLY INCLUDE: ventricular premature beats, supraventricular tachycardia, cardiomyopathy and sudden death.This study confirms the necessity for close cardiac monitoring of patients undergoing anthracycline therapy. Such monitoring should not only comprise echocardiographic monitoring for left ventricular systo-diastolic dysfunction, but also electrocardiographic monitoring (QTc) in order to exclude electrophysiological changes possibly related to life threatening arrhythmias (10).
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

